Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study)

Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study) - Clinical effect of everolimus and somatostatin analogues for patients with pNET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010395

Enrollment

Registered

2013-04-08

Start date

2013-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with unresectable or metastatic pNET

Interventions

Combined therapy of evelrolimus and somatostatin analogue

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.pathologically proved NET 2.unresectable disease 3.no prior therapy 4.ECOG performance status 0-2 5.target lesion on RECIST 6.Adequate organ function 7.Written informed consent

Exclusion criteria

Exclusion criteria: 1.past history of allergy for everolimus or somatostatin analogue 2.inaduquate organ function 3.steroids or immunosuppressive thrapy 4.Pregnant females, possibly pregnant females

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026